Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
Primary Purpose
Patent Ductus Arteriosus, Duct-dependent Cyanotic Congenital Heart Disease
Status
Unknown status
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Iron biocorrodable coronary scaffold system
Sponsored by
About this trial
This is an interventional treatment trial for Patent Ductus Arteriosus
Eligibility Criteria
Inclusion Criteria:
- Weight >3.0 kg
- Age <3 months
- Patients with uncomplicated PDA morphology (the PDA is not tortuous i.e. relatively straight
Exclusion Criteria:
- Weight <3 kg, age >3 months
- Angiographic criteria-tortuous PDA
- Family history of diseases related to iron overload or iron disorder e.g. hereditary hemochromatosis
- Other severe congenital anomalies with life expectancy <12 months
Sites / Locations
- Institut Jantung Negara
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
IBS implantation
Arm Description
Implantation of IBS in PDA in duct-dependent cyanotic CHD
Outcomes
Primary Outcome Measures
Number of participants for surgical repair of CHD
Patients are subjected for surgical repair of CHD
Number of Unplanned re-intervention
Unplanned re-intervention with additional stenting procedure
Death
Death before surgical repair
Secondary Outcome Measures
Full Information
NCT ID
NCT04291222
First Posted
February 28, 2020
Last Updated
February 28, 2020
Sponsor
Lifetech Scientific (Shenzhen) Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04291222
Brief Title
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
Official Title
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Unknown status
Study Start Date
December 11, 2018 (Actual)
Primary Completion Date
August 2020 (Anticipated)
Study Completion Date
August 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lifetech Scientific (Shenzhen) Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a pilot study on feasibility, efficacy and safety of IBS ® for implantation in the PDA in duct-dependent cyanotic CHD, and its objective is to investigate the feasibility, safety and efficacy of iron resorbable stent implantation in the PDA as initial palliation of cyanotic CHD with duct-dependent PBF.
Detailed Description
Study type: Interventional, prospective, single arm, investigator initiated Study population: 10 patients Primary purpose: Treatment Follow up: Review at 1 month and thereafter 3 monthly (clinical examination and echocardiography for stent patency, SaO2 measurement. Serum Iron and Ferritin levels will be measured before procedure and at follow ups. From 6 months onwards the patients will be assessed for the need of repeat catheterization with a view of surgery or for continued observation.
Study endpoints: 9 months post implant or the following: 1)Patients are subjected for surgical repair of CHD; 2)Death before surgical repair; 3)Unplanned re-intervention with additional stenting procedure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patent Ductus Arteriosus, Duct-dependent Cyanotic Congenital Heart Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
IBS implantation
Arm Type
Experimental
Arm Description
Implantation of IBS in PDA in duct-dependent cyanotic CHD
Intervention Type
Device
Intervention Name(s)
Iron biocorrodable coronary scaffold system
Intervention Description
Implantation of Iron biocorrodable coronary scaffold system
Primary Outcome Measure Information:
Title
Number of participants for surgical repair of CHD
Description
Patients are subjected for surgical repair of CHD
Time Frame
9 months
Title
Number of Unplanned re-intervention
Description
Unplanned re-intervention with additional stenting procedure
Time Frame
9 months
Title
Death
Description
Death before surgical repair
Time Frame
9 months
10. Eligibility
Sex
All
Maximum Age & Unit of Time
3 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Weight >3.0 kg
Age <3 months
Patients with uncomplicated PDA morphology (the PDA is not tortuous i.e. relatively straight
Exclusion Criteria:
Weight <3 kg, age >3 months
Angiographic criteria-tortuous PDA
Family history of diseases related to iron overload or iron disorder e.g. hereditary hemochromatosis
Other severe congenital anomalies with life expectancy <12 months
Facility Information:
Facility Name
Institut Jantung Negara
City
Kuala Lumpur
Country
Malaysia
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
We'll reach out to this number within 24 hrs